Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

Por Negrier, Claude, Voisin, Sophie, Baghaei, Fariba, Numerof, Robert, Novack, Aaron, Doralt, Jennifer E., Romanov, Vadim, Gringeri, Alessandro
Publicado no Blood Coagul Fibrinolysis (2016)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease

Por Gelmont, David, Thomas, Ronald G., Britt, Jonathan, Dyck-Jones, Jacqueline A., Doralt, Jennifer, Fritsch, Sandor, Brewer, James B., Rissman, Robert A., Aisen, Paul
Publicado no Alzheimers Dement (N Y) (2016)

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Por Scully, Marie, Knöbl, Paul, Kentouche, Karim, Rice, Lawrence, Windyga, Jerzy, Schneppenheim, Reinhard, Hovinga, Johanna A. Kremer, Kajiwara, Michiko, Fujimura, Yoshihiro, Maggiore, Caterina, Doralt, Jennifer, Hibbard, Christopher, Martell, Leah, Ewenstein, Bruce
Publicado no Blood (2017)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

Por Hillson, Jan, Mant, Tim, Rosano, Molly, Huntenburg, Carolyn, Alai‐Safar, Mehrshid, Darne, Siddhesh, Palmer, Donna, Pavlova, Borislava G., Doralt, Jennifer, Reeve, Russell, Goel, Niti, Weilert, Doris, Rhyne, Paul W., Chance, Kamali, Caminis, John, Roach, James, Ganguly, Tanmoy
Publicado no Pharmacol Res Perspect (2018)